Clinical Psychopharmacology and Neuroscience Papers in Press available online.

 
The Korean Medication Algorithm Project for Depressive Disorder 2021 (KMAP-DD 2021): Comparisons with Other Treatment Guidelines
Young Sup Woo 1, Won-Myong Bahk 1,*, Jeong Seok Seo 2, Young-Min Park 3, Won Kim 4, Jong-Hyun Jeong 1, Se-Hoon Shim 5, Jung-Goo Lee 6, Seung-Ho Jang 7, Chan-Mo Yang 7, Sheng-Min Wang 1, Myung Hun Jung 8, Hyung Mo Sung 9, Il Han Choo 10, Bo-Hyun Yoon 11, Sang-Yeol Lee 7, Duk-In Jon 8, Kyung Joon Min 2
1Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea , 2Department of Psychiatry, College of Medicine, Chung-Ang University, Seoul, Korea, 3Department of Psychiatry, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea, 4Department of Psychiatry, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea, 5Department of Psychiatry, Soonchunhyang University Cheonan Hospital, College of Medicine, Soonchunhyang University, Cheonan, Korea, 6Department of Psychiatry, Haeundae Paik Hospital, College of Medicine, Inje University, Busan, Korea, 7Department of Psychiatry, Wonkwang University Hospital, School of Medicine, Wonkwang University, Iksan, Korea, 8Department of Psychiatry, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea, 9Department of Psychiatry, Soonchunhyang University Gumi Hospital, College of Medicine, Soonchunhyang University, Gumi, Korea, 10Department of Neuropsychiatry, College of Medicine, Chosun University, Korea Department of Psychiatry, Chosun University Hospital, Gwangju, Korea, 11Department of Psychiatry, Naju National Hospital, Naju, Korea
Abstract
The Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) first was published in 2002, and has been revised four times, in 2006, 2012, 2017, and 2021. In this review, we compared recommendations from the recently revised KMAP-DD 2021 to four global clinical practice guidelines (CPGs) for depression published after 2010. The recommendations from the KMAP-DD 2021 were similar to those from other CPGs, although there were some differences. The KMAP-DD 2021 reflected social culture and the healthcare system in Korea and recent evidence about pharmacotherapy for depression, as did other recently published evidence-based guidelines. Despite some intrinsic limitations as an expert consensus-based guideline, the KMAP-DD 2021 can be helpful for Korean psychiatrists making decisions in clinical settings by complementing previously published evidence-based guidelines, especially for some clinical situations lacking evidence from rigorously designed clinical trials.
Accepted Manuscript [Submitted on 2021-09-23, Accepted on 2021-10-13]